Literature DB >> 17103173

The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study.

F Yalçinkaya1, N Cakar, B Acar, E Tutar, H Güriz, A H Elhan, S Oztürk, A Kansu, E Ince, S Atalay, N Girgin, U Doğru, D Aysev, M Ekim.   

Abstract

In order to determine the role of levels of acute phase proteins (APPs) for the development of amyloidosis in familial Mediterranean fever (FMF) patients, the levels of serum amyloid A (SAA), C reactive protein (CRP), fibrinogen and erythrocyte sedimentation rate were measured in paired sera of 36 FMF patients during and in between acute attacks, 39 of their healthy parents (obligate heterozgotes), and 15 patients with FMF associated amyloidosis. To compare the levels of APPs, 39 patients with chronic infections or inflammatory diseases who may develop secondary amyloidosis, 20 patients with acute infections who are known to have elevated acute phase response but will never develop amyloidosis and 19 healthy controls were included. The median levels of all APPs are increased in the patients with FMF during attacks and a significant decrease was observed after the attack was over. The level of SAA was above reference range in all FMF patients during the attack free period and the level of at least one other APP was also above normal in 64% of the patients. Both CRP and SAA levels were found to be higher in obligate heterozygotes compared to controls. The levels of SAA in patients with FMF during the attack-free period, obligate heterozygotes and patients with FMF-amyloidosis were found to be similar. The levels in each group were found to be higher than SAA levels found in healthy controls yet lower than the levels measured in the patients with acute infections and patients with chronic inflammation or chronic infections. In conclusion, our results show that SAA level reflects subclinical inflammation with high sensitivity but its value for the prediction of amyloid formation process seems to be low.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103173     DOI: 10.1007/s00296-006-0265-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Acute phase response and evolution of familial Mediterranean fever.

Authors:  M Tunca; G Kirkali; M Soytürk; S Akar; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  1999-04-24       Impact factor: 79.321

2.  Familial Mediterranean fever and systemic amyloidosis in untreated Turkish patients.

Authors:  F Yalçinkaya; M Tekin; N Cakar; E Akar; N Akar; N Tümer
Journal:  QJM       Date:  2000-10

3.  MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications.

Authors:  C Cazeneuve; T Sarkisian; C Pêcheux; M Dervichian; B Nédelec; P Reinert; A Ayvazyan; J C Kouyoumdjian; H Ajrapetyan; M Delpech; M Goossens; C Dodé; G Grateau; S Amselem
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

4.  Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever.

Authors:  C Cazeneuve; H Ajrapetyan; S Papin; F Roudot-Thoraval; D Geneviève; E Mndjoyan; M Papazian; A Sarkisian; A Babloyan; B Boissier; P Duquesnoy; J C Kouyoumdjian; E Girodon-Boulandet; G Grateau; T Sarkisian; S Amselem
Journal:  Am J Hum Genet       Date:  2000-10-03       Impact factor: 11.025

5.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

Review 6.  Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.

Authors:  J Samuels; I Aksentijevich; Y Torosyan; M Centola; Z Deng; R Sood; D L Kastner
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

7.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.

Authors:  A Duzova; A Bakkaloglu; N Besbas; R Topaloglu; S Ozen; F Ozaltin; Y Bassoy; E Yilmaz
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

8.  Correlations between serum amyloid A protein and C-reactive protein in infectious diseases.

Authors:  A Lannergård; A Larsson; P Kragsbjerg; G Friman
Journal:  Scand J Clin Lab Invest       Date:  2003       Impact factor: 1.713

9.  Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial mediterranean fever in the Turkish population.

Authors:  Aysin Bakkaloglu; Ali Duzova; Seza Ozen; Banu Balci; Nesrin Besbas; Rezan Topaloglu; Fatih Ozaltin; Engin Yilmaz
Journal:  J Rheumatol       Date:  2004-06       Impact factor: 4.666

10.  Serum amyloid A1 and tumor necrosis factor-alpha alleles in Turkish familial Mediterranean fever patients with and without amyloidosis.

Authors:  Nejat Akar; Metis Hasipek; Ece Akar; Mesiha Ekim; Fatos Yalçinkaya; Nilgün Cakar
Journal:  Amyloid       Date:  2003-03       Impact factor: 7.141

View more
  12 in total

1.  The value of procalcitonin measurements in children with familial Mediterranean fever.

Authors:  Selçuk Yüksel; Mesiha Ekim; Z Birsin Ozçakar; Fatoş Yalçınkaya; Banu Acar; Derya Oztuna; Nejat Akar
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

2.  Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.

Authors:  Mustafa Çakan; Nuray Aktay Ayaz; Gonca Keskindemirci; Şerife Gül Karadağ; Ayşe Tanatar; Hafize Emine Sönmez
Journal:  Clin Rheumatol       Date:  2019-09-04       Impact factor: 2.980

Review 3.  What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review.

Authors:  Burak Erer; Erkan Demirkaya; Seza Ozen; Tilmann Kallinich
Journal:  Rheumatol Int       Date:  2015-12-28       Impact factor: 2.631

4.  TLR polymorphisms in FMF: association of TLR-2 (Arg753Gln) and TLR-4 (Asp299Gly, Thre399Ile) polymorphisms and myeloid cell TLR-2 and TLR-4 expression with the development of secondary amyloidosis in FMF.

Authors:  Alper Soylu; Halil Ateş; Sultan Cingöz; Mehmet Türkmen; Belde Kasap Demir; Mehmet Tunca; Meral Sakızlı; Mustafa Cirit; Rıfkı Ersoy; Ayfer Ulgenalp; Salih Kavukçu
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

5.  Can RDW be used as a screening test for subclinical inflammation in children with FMF? Is RDW related to MEFV gene mutations?

Authors:  Gönül Parmaksız; Z Aytül Noyan
Journal:  Clin Rheumatol       Date:  2022-09-14       Impact factor: 3.650

6.  Oral involvement in a case of AA amyloidosis: a case report.

Authors:  M Inanç Cengiz; Hom-Lay Wang; Levent Yıldız
Journal:  J Med Case Rep       Date:  2010-06-30

7.  Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever.

Authors:  Hale Sakallı; Oznur Kal
Journal:  Clin Rheumatol       Date:  2013-04-17       Impact factor: 2.980

8.  Serum galectin-3 levels were associated with proteinuria in patients with Familial Mediterranean Fever.

Authors:  Hakki Yilmaz; Osman Inan; Tahir Darcin; Mukadder Ayse Bilgic; Ali Akcay
Journal:  Clin Exp Nephrol       Date:  2014-07-25       Impact factor: 2.801

9.  Left ventricular diastolic function evaluated with tissue Doppler imaging in children with familial Mediterranean fever.

Authors:  Tamer Baysal; Harun Peru; Bulent Oran; Tahir Kemal Sahin; Yavuz Koksal; Sevim Karaaslan
Journal:  Clin Rheumatol       Date:  2008-08-08       Impact factor: 2.980

10.  Simple markers for subclinical inflammation in patients with Familial Mediterranean Fever.

Authors:  Samet Özer; Resul Yılmaz; Ergün Sönmezgöz; Erhan Karaaslan; Semanur Taşkın; İlknur Bütün; Osman Demir
Journal:  Med Sci Monit       Date:  2015-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.